News & Events about Annovis Bio.
Business Wire
10 months ago
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinsons Disease (PD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback...
TipRanks Financial Blog
12 months ago
Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Research Report) yesterday and set a price target of $26.00. The ... Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Res...
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION PR Newswire BERWYN, Pa., April 11, 2023 BERWYN, Pa., April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis' or the...
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease PR...